Blood Podcast Summary – March 6, 2025

American Society of Hematology
Main Theme:
This episode explores cutting-edge hematology research summarized from the latest issues of Blood. The focus is on:

• Mutations in AMBRA1 as aggravators of β-thalassemia via impaired autophagic clearance of toxic proteins
• Targeting MYD88 L265P mutations in B cell lymphomas with a new small molecule
• The link between air pollution and increased risk of venous thromboembolism (VTE)

1. Mutations in AMBRA1 Exacerbate β-Thalassemia

Discussion: 00:30–08:40
Key Points:

• Pathophysiology Background:

  • β-thalassemia results from HBB gene mutations causing reduced β-globin, surplus toxic α-globin, ineffective erythropoiesis, and hemolysis.
  • Autophagy (cellular recycling) helps clear free α-globin and may modify disease severity.

• Research Highlight:

  • Study: Yong Long (Southern Medical University, China) and colleagues analyzed 1,022 β-thalassemia patients, screening 30 autophagy-related genes.
  • Identified four rare AMBRA1 missense mutations associated with worse anemia, lower RBC count, lower hematocrit, and greater splenomegaly.
  • In mouse and cell models, normal AMBRA1 enhanced autophagy, cleared free α-globin, reduced toxicity; AMBRA1 mutations impaired autophagy, increased toxic protein buildup, apoptosis, ROS levels, and blocked erythroid cell maturation.

• Mechanistic Insight:

  • Mutated AMBRA1 destabilized ULK1 (primary autophagy activator).
  • Mutations also inhibited LC3 lipidation initiation step.

• Clinical Implications:

  • Suggests AMBRA1 as both a diagnostic and therapeutic target, especially for those without access to gene therapy or transplants.

Notable Quotes:

“AMBRA1 performs a balancing act so to speak in beta thalassemia. Ambra1 adds to the repertoire of known genetic modifiers that influence the severity of beta thalassemia.”
— Commentary by Christophe Lekov and Mitchell J. Weis (07:45)

“This study provides the strongest evidence to date that autophagy of free alpha globin reduces the severity of human beta thalassemia.”
— Commentary, Christophe Lekov & Mitchell J. Weis (08:02)

Memorable Moment:

• Expanding the therapeutic paradigm for β-thalassemia to include autophagy-modulating drugs, positioning protein quality control as a major research avenue (08:20).

2. Targeting MYD88L265P in B-cell Lymphomas with Lesalosid A

Discussion: 08:41–16:00
Key Points:

• Background:

  • MYD88L265P is a common activating mutation in B-cell lymphomas (Waldenstrom macroglobulinemia – 90%, DLBCL – 25%, CNS lymphoma – 70%).
  • Past inhibitors mostly interfered with protein-protein interactions or gene expression, but few directly targeted mutant protein degradation.

• Research Highlight:

  • Study: Wei Li (Central South University, China) and team used high-throughput screening to identify lesalosid A, a small molecule that binds specifically to MYD88L265P but not wild-type MYD88.
  • Lesalosid A enhances interaction with E3 ligase RNF5, mediating ubiquitin-dependent proteasomal degradation.
  • In preclinical models, lesalosid A:
    • Selectively killed mutant lymphoma cells
    • Induced remission in ibrutinib-resistant lymphomas
    • Synergized with BCL2 inhibitor venetoclax

• Clinical Commentary:

  • Joost S.P. Vermat and Ruben Al Degron (Leiden University Medical Center, Netherlands):
    • Lesalosid A is a promising therapy for high-risk DLBCL that could improve selectivity and reduce toxicity compared to chemotherapy.
    • May benefit primary CNS lymphoma patients if brain penetration is confirmed.
    • Notable for synergy with venetoclax, but toxicity and survival impact require further study.

Notable Quotes:

“A therapy that selectively targets tumor B cells rather than healthy B cells would be highly advantageous.”
— Joost S.P. Vermat & Ruben Al Degron (14:08)

“Adding Lesalosid A to venetoclax-based combination regimens could enhance treatment efficacy, they say, though the potential toxicity and impact on survival would need to be quantified.”
— Commentary, Vermat & Al Degron (15:32)

Memorable Moment:

• Lesalosid A may provide options for ibrutinib-refractory cases—an urgent clinical need (13:50).

3. Air Pollution Raises Risk of Venous Thromboembolism (VTE)

Discussion: 16:01–22:25
Key Points:

• Background:

  • Pollution is linked to cardiovascular disease; its connection to VTE is less established.
  • VTE, including deep vein thrombosis and pulmonary embolism, affects ~1 million Americans annually.

• Research Highlight:

  • Study: Pamela L. Lutze (Univ. of Minnesota) with the Multiethnic Study of Atherosclerosis (MESA): >6,500 U.S. adults, followed up to 18.5 years.
  • Exposure assessments for fine particulate matter (PM2.5), nitrogen oxides (NOx), nitrogen dioxide, and ozone; VTE identified from hospital records.
  • Findings:
    • Chronic exposure to air pollution increases VTE risk:
      • +3.6 μg/m³ PM2.5 → Hazard Ratio (HR) 1.39 (CI: 1.04–1.86)
      • +13.3 ppb NO2 → HR 2.74 (CI: 1.57–4.77)
      • +30 ppb NOx → HR 2.21 (CI: 1.42–3.44)
      • No significant association with ozone

• Expert Commentary:

  • Ingrid Pabinger & Sihan Ay (Med. Univ. of Vienna):
    • Study deepens concern: “its hidden dangers to human health are even more alarming... millions of air pollution-related deaths worldwide.”
    • Limitations: VTE cases limited to hospitalized patients; no distinction between DVT and PE.
    • Nonetheless, research is “reliable and valuable,” highlighting the imperative for cleaner air (21:40).

Notable Quotes:

“While the visible smog of air pollution is concerning, its hidden dangers to human health are even more alarming.”
— Ingrid Pabinger & Sihan Ay (21:30)

“A holistic approach incorporating renewable energy, mass transit, green spaces and reduced urbanization could help mitigate air pollution and potentially lower the risk of VTE.”
— Ingrid Pabinger & Sihan Ay (22:05)

Memorable Moment:

• Epidemiologic “bottom line”: Even modest increases in pollution may confer significant public health burden given the ubiquity of exposure (19:55).

Summary Table: Major Takeaways and Timestamps

| Topic | Major Finding/Implication | Notable Commentary / Quote | Timestamp | |------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------|------------| | AMBRA1 in β-thalassemia | Mutations worsen disease via impaired autophagy, highlighting AMBRA1 as therapeutic target | “Balancing act... strongest evidence to date...” | 07:45–08:10| | Lesalosid A for Lymphoma | Selective degradation of MYD88L265P, synergistic with venetoclax; potential for CNS lymphoma | “Selectively targets tumor B cells...” | 13:55–15:32| | Air Pollution & VTE | Chronic exposure increases VTE risk; supports call for pollution reduction | “Hidden dangers... even more alarming.” | 21:30–22:05|

Overall Tone

Balanced, expert-driven, and aimed at both clinicians and researchers. The speakers strive to highlight clinical implications, acknowledge limitations, and underline the broader public health and research context.

If you missed this episode, this summary captures the key findings, expert perspectives, and implications for clinical and scientific communities in hematology.